Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina

[1]  E. Pegoraro,et al.  Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy , 2019, Journal of the Neurological Sciences.

[2]  Jin-Sung Park,et al.  Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients , 2019, Neurological Sciences.

[3]  C. Jackson,et al.  Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch , 2019, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[4]  C. Quarracino,et al.  Predictors of amyotrophic lateral sclerosis mimic syndrome , 2019, Acta Neurologica Belgica.

[5]  J. Turnbull.  Author response to a Letter to the Editor entitled: Edaravone administration in pivotal clinical study 19 (Authors: Genge, Angela; Brooks, Benjamin) , 2019, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[6]  V. Drory,et al.  Early post-marketing experience with edaravone in an unselected group of patients with ALS , 2019, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[7]  M. Jaiswal,et al.  Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs , 2018, Medicinal research reviews.

[8]  Huiwang,et al.  Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis—a systematic review and meta-analysis , 2018, Neurological Sciences.

[9]  Yukio Ando,et al.  Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis , 2018, eNeurologicalSci.

[10]  Ahmad Al Khleifat,et al.  Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study , 2018, The Lancet Neurology.

[11]  M. Kuźma-Kozakiewicz.  Edaravone in the treatment of amyotrophic lateral sclerosis. , 2018, Neurologia i neurochirurgia polska.

[12]  A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[13]  Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[14]  A. Al-Chalabi,et al.  July 2017 ENCALS statement on edaravone , 2017, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[15]  Y. Itoyama,et al.  Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial , 2017, The Lancet Neurology.

[16]  O. Hardiman,et al.  Edaravone: a new treatment for ALS on the horizon? , 2017, The Lancet Neurology.

[17]  Yasuto Itoyama,et al.  Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients , 2014, Amyotrophic lateral sclerosis & frontotemporal degeneration.

[18]  M. Hennerici,et al.  Comparison of the European and Japanese Guidelines for the Management of Ischemic Stroke , 2013, Cerebrovascular Diseases.

[19]  Acary Souza Bulle Oliveira,et al.  Amyotrophic lateral sclerosis (ALS): three letters that change the people's life. For ever. , 2009, Arquivos de neuro-psiquiatria.

[20]  H. Yoshino,et al.  Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study) , 2006, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[21]  R. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.